Protego Biopharma Raises $130 Million in Oversubscribed Series B Financing

Cooley LLP advised Protego Biopharma on its Series B financing. San Diego — December 1, 2025 — Protego Biopharma, a clinical‑stage biotechnology company dedicated to pioneering first‑in‑class small‑molecule therapeutics that reprogram protein folding to address systemic amyloid diseases and other protein misfolding disorders, closed an oversubscribed $130 million Series B financing. The round was co‑led by Novartis Venture Fund and Forbion, with additional participation from new investors Omega Funds, Droia Ventures, YK Bioventures and Digitalis Ventures, and continued support from existing investors Vida Ventures, MPM BioImpact, Lightspeed Venture Partners and Scripps Research. Cooley LLP represented Protego Biopharma with a team composed by: Tom Coll, Edmond Lay, Summer Wynn, Annie Froehlich, Dr. Madhuri Roy, Kyrsten Lundh, Rebeca Kinslow and John Sellers, who led the engagement. The broader Cooley team included Michael Egan, Asa Henin, Christopher Kimball, Andrew Epstein, Mari Dugas, Richard Koch, Dr. Asako Kubota, Vittoria Rainone, Jack Whitaker, Patricia Bresnan, Kate Walther, Brian Mitchell, Jake Ironfield, Katie Kissner and Dr. Mengran Liu. Cooley previously advised Protego on its $51 million Series A financing in November 2021.

Protego Biopharma Raises $130 Million in Oversubscribed Series B Financing

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads